Femasys Inc
FEMY0.861USD
+0.064+7.97%
收盘 12/19, 16:00（美东）报价延迟15分钟
40.73M总市值
亏损市盈率 TTM
关于 Femasys Inc 公司
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Femasys Inc简介
公司代码FEMY
公司名称Femasys Inc
上市日期Jun 18, 2021
CEOLee-Sepsick (Kathy)
员工数量69
证券类型Ordinary Share
年结日Jun 18
公司地址3950 Johns Creek Court
城市SUWANEE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编30024
电话17705003910
网址https://www.femasys.com/
公司代码FEMY
上市日期Jun 18, 2021
CEOLee-Sepsick (Kathy)
Femasys Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
409.27K
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Chernett (Jorey)
5.19%
Dauntless Investment Group, LLC
2.96%
Uzialko (Edward R Jr.)
2.08%
The Vanguard Group, Inc.
1.63%
Alumni Capital Management LLC
1.59%
其他
86.55%
持股股东
持股股东
占比
Chernett (Jorey)
5.19%
Dauntless Investment Group, LLC
2.96%
Uzialko (Edward R Jr.)
2.08%
The Vanguard Group, Inc.
1.63%
Alumni Capital Management LLC
1.59%
其他
86.55%
股东类型
持股股东
占比
Individual Investor
8.41%
Investment Advisor
5.54%
Investment Advisor/Hedge Fund
2.29%
Venture Capital
0.08%
Research Firm
0.04%
Bank and Trust
0.03%
Hedge Fund
0.03%
其他
83.57%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
53
6.06M
9.41%
--
2025Q3
60
6.06M
10.92%
+931.90K
2025Q2
65
5.13M
15.23%
+1.22M
2025Q1
62
3.90M
17.97%
-962.46K
2024Q4
57
2.39M
11.54%
+713.58K
2024Q3
55
1.67M
11.99%
+32.62K
2024Q2
57
1.64M
11.51%
+117.87K
2024Q1
57
1.52M
11.83%
-1.09M
2023Q4
56
1.43M
10.18%
-232.64K
2023Q3
51
1.66M
10.47%
+405.22K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Chernett (Jorey)
3.03M
7.05%
+1.41M
+86.81%
Jun 30, 2025
Dauntless Investment Group, LLC
2.32M
5.4%
+745.63K
+47.34%
Jun 30, 2025
Uzialko (Edward R Jr.)
1.22M
2.83%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
951.87K
2.21%
+126.20K
+15.28%
Jun 30, 2025
Alumni Capital Management LLC
931.90K
2.17%
+931.90K
--
Sep 04, 2025
Lee-Sepsick (Kathy)
432.85K
1.01%
+48.53K
+12.63%
Aug 27, 2025
Geode Capital Management, L.L.C.
251.39K
0.58%
+5.89K
+2.40%
Jun 30, 2025
Clear Creek Financial Management, LLC
281.82K
0.66%
+11.45K
+4.23%
Jun 30, 2025
Currie (Daniel Scott)
109.24K
0.25%
+19.61K
+21.88%
Jun 02, 2025
BlackRock Institutional Trust Company, N.A.
92.41K
0.21%
+56.73K
+159.00%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Femasys Inc的前五大股东是谁？
Femasys Inc 的前五大股东如下：
Chernett (Jorey)持有股份：3.03M，占总股份比例：7.05%。
Dauntless Investment Group, LLC持有股份：2.32M，占总股份比例：5.40%。
Uzialko (Edward R Jr.)持有股份：1.22M，占总股份比例：2.83%。
The Vanguard Group, Inc.持有股份：951.87K，占总股份比例：2.21%。
Alumni Capital Management LLC持有股份：931.90K，占总股份比例：2.17%。
Chernett (Jorey)持有股份：3.03M，占总股份比例：7.05%。
Dauntless Investment Group, LLC持有股份：2.32M，占总股份比例：5.40%。
Uzialko (Edward R Jr.)持有股份：1.22M，占总股份比例：2.83%。
The Vanguard Group, Inc.持有股份：951.87K，占总股份比例：2.21%。
Alumni Capital Management LLC持有股份：931.90K，占总股份比例：2.17%。
Femasys Inc的前三大股东类型是什么？
Femasys Inc 的前三大股东类型分别是：
Chernett (Jorey)
Dauntless Investment Group, LLC
Uzialko (Edward R Jr.)
Chernett (Jorey)
Dauntless Investment Group, LLC
Uzialko (Edward R Jr.)
有多少机构持有Femasys Inc(FEMY)的股份？
截至2025Q4，共有53家机构持有Femasys Inc的股份，合计持有的股份价值约为6.06M，占公司总股份的9.41%。与2025Q3相比，机构持股有所增加，增幅为-1.52%。
哪个业务部门对Femasys Inc的收入贡献最大？
在FY2025Q2，--业务部门对Femasys Inc的收入贡献最大，创收--，占总收入的--%。
